Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

After years of sparring, the Biden administration and Gilead Sciences have settled a contentious lawsuit over patents for a ...

Doxycycline postexposure prophylaxis has the potential to substantially reduce real-world population-level incidence of ...

Shareholders request Human Rights Due Diligence to determine whether pharma companies do everything they can to increase drug ...

Gilead’s investment will let it assess the therapeutic potential of targeting STAT6, a transcription factor involved in IL-4 ...

Gilead's chief executive calls lenacapavir a once in a decade medicine. The HIV treatment could push Gilead stock further up ...

CNBC’s Angelica Peebles and Gilead chairman and CEO Daniel O’Day join 'Squawk Box' to discuss the company's new HIV ...

Recent health news covers a proposed increase in Medicare Advantage rates, access challenges to precision cancer drugs for ...

N-Power Medicine, a company leading the reinvention of the clinical trial process, today announced the acquisition of Syapse Holdings Inc. ("Syapse"), a pioneer in precision medicine solutions for ...

Gilead Sciences, Inc. (Nasdaq: GILD) and LEO Pharma today announced a strategic partnership to accelerate the development and ...

Fintel reports that on January 10, 2025, Morgan Stanley upgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from Equal ...

Rising Demand for Targeted Therapies and Advancements in Genomic Technologies Propel the Personalized Medicine Biomarkers market to a 14.54% CAGR ...